Screener
Cytokinetics CYTK Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -1,046.1%-408pp | -605.1%+2,338pp | -695.4%+2,207pp | -656.9%+15,641pp | -638%+15,510pp | |
| Net margin | -1,321.1%-614pp | -784%+2,417pp | -891.6%+2,300pp | -862.2%+17,044pp | -707.2%+16,692pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0.1×+0.1× | 0.1×0.0× | 0.1×+0.1× | 0.1×+0.1× | |
| Liquidity | ||||||
| Current ratio | 6.7×-0.1× | 4.2×-1.8× | 4.5×-1.6× | 6.9×-2.4× | 6.8×-3.6× | |
| Per Share | ||||||
| Book value per share | -$1.31+57.4% | -$6.71-198% | -$5.49-354% | -$4.34-3,575% | -$3.09-411% | |
| Valuation | ||||||
| Market capitalization | $10.71B+155% | $8.12B+70.6% | $7.77B+39.9% | $6.58B+5.9% | $3.99B-37.2% | |
| Price / sales | 158.2×+109× | 76.7×-171× | 88.2×-212× | 75.4×-1,855× | 46.5×-1,979× |
FAQ
- Where do Cytokinetics's ratios come from?
- Every ratio is computed from Cytokinetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
